Unfortunately, there are currently no reliable predictive biomarker to aid in the precision of PD-1/PD-L1 therapy and excavating a curative effect predictor as useful tool for PD-1/PD-L1 application in HCC patients is urgently needed in the era of precision medicine. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.